Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius And Aurobindo Among Fresh Velcade Challengers In US

Launches Confirmed Of Subcutaneous Bortezomib Generics As Patents Set To Expire

Executive Summary

Multiple firms have launched bortezomib products for subcutaneous administration in the US, adding to competition on Takeda’s Velcade brand.

You may also be interested in...



Fresenius Kabi Introduces Cancer Copay Scheme For Generics

German pharma giant Fresenius Kabi has introduced a copay scheme for a number of its generic oncology medicines in the US, which could completely eliminate monthly costs for certain patients.

Kabi ships alternative to Takeda’s Velcade

Fresenius Kabi has realised plans to launch its 505(b)(2) hybrid bortezomib 3.5mg/vial injectable in the US, after announcing the availability of the “first and only” alternative to Takeda’s Velcade (bortezomib) intravenous injectable.

EMA Re-Examines Decisions On Prestige’s Trastuzumab And Synchron Studies

Following decisions by the EMA’s CHMP to deny Prestige Biopharma a marketing authorization for its trastuzumab biosimilar and to suspend the marketing authorizations of dozens of generics due to concerns over bioequivalence tests, the European regulator has confirmed it will review the opinions.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel